Leprosy (ICD-11: 1B20) - Complete Clinical Coding Guide

1. Introduction

Leprosy, also historically known as Hansen's disease, is a chronic granulomatous infection caused by Mycobacterium leprae, an acid-fast bacillus with particular affinity for peripheral nerves and skin. This ancient disease remains an important global public health problem, primarily affecting populations in socioeconomic vulnerability and with limited access to health services.

The most striking characteristic of leprosy is its ability to cause granulomatous lesions that manifest on the skin, mucous membranes, and particularly in peripheral nerves. The clinical spectrum of the disease is extraordinarily broad, ranging from paucibacillary forms with few cutaneous lesions to multibacillary forms with extensive dissemination. This variability is directly related to the host's cellular immune response to the pathogen.

The most devastating impact of leprosy does not necessarily reside in mortality, but rather in the morbidity and permanent disabilities it can cause. Damage to motor and sensory peripheral nerves results in loss of sensation, muscle weakness, deformities and ulcers, frequently leading to functional disability and persistent social stigma associated with the disease.

Appropriate coding of leprosy using the ICD-11 code 1B20 is fundamental for global epidemiological monitoring, appropriate resource allocation, planning of control and elimination programs, and ensuring that patients receive adequate treatment and necessary follow-up to prevent complications. Accurate documentation is also essential for clinical research and development of new therapeutic strategies.

2. Correct ICD-11 Code

Code: 1B20

Description: Leprosy

Parent category: Mycobacterial diseases

Official definition: Leprosy is a chronic granulomatous infection caused by Mycobacterium leprae. The characteristic granulomatous lesions manifest primarily on the skin, in the mucous membranes of the upper airways, and in peripheral nerves. Clinical manifestations are highly dependent on the individual's immunological response to the infection, determining the spectrum of presentations that ranges from localized to disseminated forms.

Much of the disability caused by leprosy results from progressive damage to motor and sensory peripheral nerves. This damage may occur insidiously during the natural course of the disease or acutely during reactional episodes. Lepromatous neuropathy is characteristic and distinctive, presenting a specific pattern of involvement with palpable thickening of superficial nerve trunks.

Code 1B20 encompasses all clinical forms of leprosy, including indeterminate, tuberculoid, borderline, and lepromatous forms, as well as neurological complications and reactional states associated with the disease. The operational classification into paucibacillary and multibacillary, although important for therapeutic purposes, is encompassed within this main code.

3. When to Use This Code

Code 1B20 should be used in specific clinical situations where there is diagnostic confirmation of leprosy. Below, we present detailed practical scenarios:

Scenario 1: Patient with hypochromic skin lesions and loss of sensation A patient presents with whitish or brownish patches on the skin, with loss of thermal, pain, and tactile sensation in the affected areas. On physical examination, thickening of peripheral nerves is identified, particularly the ulnar or common fibular nerve. Dermoscopic bacilloscopy may be positive or negative, but the presence of the characteristic triad (skin lesion with sensory alteration, neural thickening, and bacilloscopy) confirms the diagnosis. This is the classic scenario for application of code 1B20.

Scenario 2: Confirmed histopathological diagnosis A patient with suspected skin lesions undergoes skin biopsy. Histopathological examination reveals characteristic granulomas with infiltrate of epithelioid cells and lymphocytes, in addition to acid-fast bacilli identified by Fite-Faraco staining. Histopathological confirmation of leprosy, even in the absence of positive bacilloscopy on dermal scraping, fully justifies the use of code 1B20.

Scenario 3: Pure neural leprosy A patient presents with thickening and pain in peripheral nerve trunks, with sensory and/or motor deficit in the corresponding territory, but without visible skin lesions. Neural biopsy or imaging studies demonstrate neuritis compatible with leprosy, and other differential diagnoses have been excluded. This pure neural form of leprosy, although less common, should also be coded as 1B20.

Scenario 4: Leprosy reactional states A patient undergoing treatment or with a previous history of leprosy develops erythema nodosum leprosum (type 2 reaction) or reversal reaction (type 1 reaction), characterized by acute inflammatory skin lesions and/or acute neuritis. These reactional episodes are complications of leprosy itself and should be coded as 1B20, with additional codes that may be added to specify complications when available.

Scenario 5: Diagnosis by molecular methods In situations where bacilloscopy is negative but there is strong clinical suspicion, molecular detection of M. leprae DNA through techniques such as PCR in skin samples or biopsy definitively confirms the diagnosis. With the increasing availability of molecular methods, this scenario becomes increasingly relevant, especially in paucibacillary forms, justifying the use of code 1B20.

Scenario 6: Late sequelae and complications Patients who have completed treatment but present with permanent sequelae such as deformities in hands or feet, chronic plantar ulcers, or residual facial paralysis should have these conditions documented together with the history of leprosy (1B20), indicating that the complications are direct consequences of the previously treated disease.

4. When NOT to Use This Code

It is fundamental to distinguish leprosy from other conditions that may present with similar clinical manifestations:

Other cutaneous mycobacterioses: Infections caused by nontuberculous mycobacteria, such as Mycobacterium marinum, M. ulcerans, or M. avium-intracellulare, can cause granulomatous cutaneous lesions. However, these do not cause the characteristic pattern of peripheral neuropathy seen in leprosy and should be coded as 1B21 (Infections due to nontuberculous mycobacteria). Specific microbiological identification of the agent is crucial for this differentiation.

Cutaneous tuberculosis: Although caused by another mycobacterium (M. tuberculosis), cutaneous tuberculosis presents distinct histopathological and clinical characteristics. There is no characteristic neural thickening, and the pattern of cutaneous involvement is different. It should be coded with a specific code for tuberculosis, not with 1B20.

Peripheral neuropathies of other etiologies: Conditions such as diabetic neuropathy, compressive neuropathies, alcoholic neuropathy, or neuropathies due to nutritional deficiencies can cause sensory and motor deficits. The absence of characteristic cutaneous lesions, typical neural thickening, and microbiological or histopathological evidence of leprosy excludes the use of code 1B20.

Dermatoses with hypopigmentation: Vitiligo, pityriasis versicolor, pityriasis alba, and other dermatological conditions can cause hypochromic patches on the skin. However, these lesions maintain normal sensitivity and do not present associated neural thickening. Preservation of cutaneous sensation is a fundamental distinguishing feature.

Sarcoidosis: This systemic granulomatous disease may present with cutaneous lesions and peripheral neuropathy, potentially mimicking leprosy. However, the histopathological pattern is distinct (noncaseating granulomas without bacilli), there is frequently systemic involvement (pulmonary, lymph node), and microbiological tests for M. leprae are negative.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of leprosy is essentially clinical, based on the identification of cardinal signs. The healthcare professional must perform a complete dermatological examination, seeking skin lesions with altered sensitivity. The sensitivity test should include thermal evaluation (tubes with hot and cold water), pain assessment (needle), and tactile evaluation (cotton or monofilaments).

Systematic palpation of superficial peripheral nerve trunks is fundamental: ulnar nerves (epitrochlear groove), median nerves (wrist), superficial radial nerves, common fibular nerves (fibular head), posterior tibial nerves (retromaleolar), and auricular nerves. Neural thickening, especially when asymmetric and associated with functional deficit, is highly suggestive.

Complementary diagnostic instruments include: bacilloscopy of dermal scraping (collection from ear lobes, elbows, and lesions), skin biopsy with histopathological study and special stains (Fite-Faraco, Ziehl-Neelsen), neural function tests (muscle strength test, evaluation with Semmes-Weinstein monofilaments), and when available, molecular methods such as PCR for detection of M. leprae.

Step 2: Verify specifiers

After confirming the diagnosis of leprosy, it is important to classify the clinical form according to the Ridley-Jopling classification (indeterminate, tuberculoid, dimorphous-tuberculoid, dimorphous-dimorphous, dimorphous-lepromatous, lepromatous) or according to the operational classification of the World Health Organization (paucibacillary: up to 5 skin lesions; multibacillary: more than 5 lesions).

Severity should be assessed considering: number and extent of skin lesions, degree of neural involvement (grade 0: no disability; grade 1: decreased or loss of sensitivity; grade 2: visible deformities), presence of reaction episodes, and mucosal involvement.

Disease duration should be estimated when possible, considering the patient's report on symptom onset, although there is often significant diagnostic delay due to insidious development.

Step 3: Differentiate from other codes

Tuberculosis: Although both are mycobacterioses, tuberculosis is caused by species of the M. tuberculosis complex and presents predominantly pulmonary involvement, although it may have extrapulmonary manifestations. Cutaneous tuberculosis does not cause the pattern of peripheral neuropathy characteristic of leprosy. Differentiation is made by microbiological identification of the agent, pattern of organ involvement, and response to specific immunological tests.

1B21 - Infections caused by nontuberculous mycobacteria: This code encompasses infections caused by environmental mycobacteria such as M. marinum (associated with trauma in aquatic environments), M. ulcerans (Buruli ulcer), M. avium-intracellulare (mainly in immunocompromised individuals). The fundamental differentiation is the specific microbiological identification of the causative agent and the absence of the pattern of peripheral neuropathy typical of leprosy. Clinical manifestations are generally more localized and do not present the characteristic neural thickening.

Step 4: Required documentation

Adequate documentation for coding with 1B20 should include:

Mandatory checklist:

Detailed description of skin lesions (number, location, characteristics, altered sensitivity)
Result of neurological evaluation (thickened nerves, sensory and motor deficits, degree of disability)
Result of dermal scraping bacilloscopy (bacillary index, if applicable)
Histopathological report when biopsy was performed
Operational classification (paucibacillary or multibacillary)
Presence or absence of reaction episodes
Degree of physical disability at the time of diagnosis
Date of symptom onset (when possible to determine)
Treatment instituted and therapeutic scheme used

Adequate documentation allows not only correct coding, but also monitoring of clinical evolution, assessment of therapeutic response, and early identification of complications.

6. Complete Practical Example

Clinical Case:

A 42-year-old male farmer presents to medical care reporting the appearance of skin patches approximately 18 months ago. He reports that initially he noticed a whitish patch on his right forearm, which did not cause significant symptoms. Over the past six months, he has observed the emergence of new lesions in different parts of the body and has begun to notice decreased strength in his right hand, with difficulty holding small objects.

On dermatological physical examination, eight cutaneous lesions are identified distributed asymmetrically: three on the trunk (scapular and lumbar regions), two on the upper limbs (right forearm and left arm), and three on the lower limbs (right thigh and legs). The lesions present varied characteristics: some are well-demarcated hypochromic, others erythematous with raised borders. Sensibility testing reveals loss of thermal, painful, and tactile sensation in all examined lesions.

Palpation of peripheral nerves reveals bilateral thickening of the ulnar nerves, more pronounced on the right, with pain on palpation. The right common fibular nerve also presents discrete thickening. Functional assessment demonstrates weakness of the intrinsic musculature of the right hand (difficulty with abduction of the 5th digit) and decreased dorsiflexion strength of the right foot.

Bacilloscopy of dermal scrapings was performed at six sites (ear lobes, elbows, and two cutaneous lesions), with positive results at four sites, presenting a bacilloscopic index of 3+. Biopsy of a cutaneous lesion on the forearm revealed granulomatous dermal infiltrate with epithelioid cells, lymphocytes, and numerous acid-fast bacilli resistant to Fite-Faraco staining, confirming the histopathological diagnosis of lepromatous leprosy.

Step-by-Step Coding:

Criteria analysis:

Cutaneous lesions with sensory alteration: Present - eight lesions with confirmed sensory loss
Neural thickening: Present - bilateral ulnar nerves and right common fibular nerve
Positive bacilloscopy: Present - BI 3+ (multibacillary form)
Histopathological confirmation: Present - pattern compatible with lepromatous leprosy

Code selected: 1B20 - Leprosy

Complete justification:

The patient meets all diagnostic criteria for leprosy. The presence of multiple cutaneous lesions (more than five) with sensory alteration, associated with palpable neural thickening and positive bacilloscopy, definitively establishes the diagnosis. Histopathological confirmation reinforces diagnostic certainty and allows classification as the lepromatous form (multibacillary).

The operational classification is multibacillary (more than 5 lesions and elevated positive BI), which determines the appropriate therapeutic regimen. The degree of disability is 1 (decreased sensation and muscle strength without visible deformities yet established), indicating the need for rigorous follow-up to prevent disabilities.

Applicable complementary codes:

Although the primary code is 1B20, codes may be added to specify complications when the coding system allows, such as codes for specific peripheral neuropathy or for degree of physical disability, as available in the system used.

7. Related Codes and Differentiation

Within the Same Category:

Tuberculosis: Tuberculosis and leprosy are both mycobacterioses, but caused by different species of mycobacteria. Tuberculosis, caused primarily by M. tuberculosis, presents predominantly with pulmonary manifestations (cough, sputum production, hemoptysis, evening fever), although it can have extrapulmonary forms (pleural, lymph node, bone, meningeal). The fundamental differentiation is that tuberculosis does not cause the characteristic pattern of peripheral neuropathy seen in leprosy. When cutaneous tuberculosis is present, the lesions do not show loss of sensation and there is no associated neural thickening. Diagnosis is confirmed by sputum smear microscopy, culture, or molecular methods identifying M. tuberculosis, and response to tuberculin skin tests or IGRA is generally positive.

1B21 - Infections caused by nontuberculous mycobacteria: This code encompasses infections caused by opportunistic environmental mycobacteria, distinct from both M. leprae and the M. tuberculosis complex. Examples include M. marinum (swimming pool granuloma), M. ulcerans (Buruli ulcer), M. avium-intracellulare (pulmonary or disseminated infections in immunocompromised individuals), M. fortuitum, and M. chelonae (skin and soft tissue infections). The main differentiation is the absence of characteristic peripheral neuropathy and specific microbiological identification of the agent. These infections generally present with more localized manifestations, related to the site of inoculation or the host's immunological condition, without the systematized pattern of neural involvement seen in leprosy.

Differential Diagnoses:

Vitiligo: Autoimmune disease characterized by achromic patches (complete loss of pigmentation) with well-defined borders, frequently symmetrical. The fundamental differentiation is that cutaneous sensitivity is preserved in vitiligo lesions, there is no neural thickening, and microbiological tests are negative.

Pityriasis versicolor: Superficial fungal infection causing hypochromic or hyperchromic patches with fine scaling. The lesions maintain normal sensation, there is no neural involvement, and direct mycological examination reveals characteristic fungal structures.

Sarcoidosis: Systemic granulomatous disease that can cause cutaneous lesions and neuropathy. Differentiation is based on histopathological pattern (noncaseating granulomas without bacilli), characteristic systemic involvement (hilar lymphadenopathy, pulmonary infiltrates), elevation of angiotensin-converting enzyme, and negative tests for M. leprae.

Diabetic neuropathy: Causes peripheral sensory loss, typically in a symmetrical "glove and stocking" pattern. There are no cutaneous lesions characteristic of leprosy, there is no palpable neural thickening, and the clinical context of diabetes mellitus is evident.

8. Differences with ICD-10

In the ICD-10 classification, leprosy is coded in category A30, with specific subdivisions for different clinical forms:

A30.0 - Indeterminate leprosy
A30.1 - Tuberculoid leprosy
A30.2 - Tuberculoid borderline leprosy
A30.3 - Borderline leprosy
A30.4 - Virchowian borderline leprosy
A30.5 - Virchowian leprosy
A30.8 - Other forms of leprosy
A30.9 - Leprosy, unspecified

The main change in ICD-11 is the simplification of coding, using the single code 1B20 for all forms of leprosy, with the possibility of specification through extension codes when necessary. This approach reflects a more integrated understanding of the disease as a continuous spectrum dependent on the host's immunological response, rather than completely separate entities.

The practical impact of this change includes simplification of the coding process, reduction of classification errors between subtypes, and greater focus on operational classification (paucibacillary versus multibacillary) that is more relevant for therapeutic decisions. The transition from ICD-10 to ICD-11 requires updating information systems and training professionals, but offers advantages in terms of consistency and ease of use.

The hierarchical structure of ICD-11 also facilitates broader epidemiological analyses, allowing data aggregation at the level of "mycobacterial diseases" when appropriate, while maintaining the possibility of detailed specification when necessary.

9. Frequently Asked Questions

1. How is leprosy diagnosed?

The diagnosis of leprosy is essentially clinical, based on the identification of at least one of the cardinal signs: skin lesion with altered sensation, peripheral nerve thickening, or positive bacilloscopy on dermal scraping. Careful physical examination is fundamental, including complete dermatological evaluation with sensibility testing on all suspected lesions and systematic palpation of superficial peripheral nerves. Complementary tests such as bacilloscopy of dermal scraping and skin biopsy with histopathological study aid in diagnostic confirmation and classification of the clinical form. Molecular methods such as PCR are increasingly available and may be useful in cases with negative bacilloscopy but strong clinical suspicion.

2. Is treatment available in public health systems?

Yes, leprosy treatment is provided free of charge through public health programs in most countries where the disease is endemic. The World Health Organization provides multidrug therapy (MDT) free of charge to national leprosy control programs. Treatment consists of standardized multidrug regimens (rifampicin, dapsone, and clofazimine for multibacillary forms; rifampicin and dapsone for paucibacillary forms) for defined periods. Access to treatment is considered a fundamental right and essential component of strategies for eliminating leprosy as a public health problem.

3. How long does treatment last?

The duration of treatment depends on the operational classification of the disease. For paucibacillary forms (up to 5 skin lesions), standard treatment lasts 6 months with 6 supervised monthly doses. For multibacillary forms (more than 5 lesions), treatment extends for 12 months with 12 supervised monthly doses. It is essential to complete the therapeutic regimen in full to ensure bacteriological cure and prevent drug resistance. After completing treatment, the patient is considered cured from a bacteriological standpoint, although prolonged follow-up may be necessary for prevention and treatment of disabilities, and surveillance for reactive episodes that may occur even after discharge from medication.

4. Can this code be used in medical certificates?

Yes, code 1B20 can and should be used in official medical documentation, including certificates, when clinically appropriate. However, it is important to consider the implications of the stigma still associated with leprosy in some communities. In situations where detailed specification of the diagnosis may cause unjustified social or occupational discrimination, more generic descriptions may be used in non-strictly clinical documents, although complete medical documentation should always be accurate. Legislation in many countries protects patients with leprosy against discrimination, and appropriately documented diagnosis can be important for ensuring rights and access to specialized services.

5. What are the main warning signs to suspect leprosy?

The main warning signs include: skin patches with altered sensation (does not feel heat, pain, or touch on the lesion), areas of skin with loss or absence of sweating, pain or thickening of peripheral nerves (mainly ulnar, fibular, and radial), decreased or loss of muscle strength in hands or feet, nodules on the body associated with fever (erythema nodosum), and numbness or tingling in hands and feet. The presence of any of these signs, especially when associated, should prompt evaluation by a specialist physician for appropriate diagnostic investigation.

6. Is leprosy contagious throughout the course of the disease?

Transmission of leprosy occurs mainly through prolonged and close contact with untreated multibacillary patients, via respiratory route (respiratory droplets). However, infectivity is relatively low, and most exposed people do not develop the disease due to natural resistance. After starting multidrug therapy, the capacity for transmission decreases rapidly, and after the first doses, the patient is no longer considered a source of infection. Therefore, social isolation is not necessary or recommended. Paucibacillary forms have minimal or no capacity for transmission even before treatment.

7. What are the main complications of leprosy?

The most significant complications are physical disabilities resulting from damage to peripheral nerves. These include: loss of sensation in hands and feet leading to unperceived injuries and ulcers, muscle weakness causing deformities (claw hand, foot drop, lagophthalmos), progressive bone resorption in extremities, blindness from ocular involvement (lagophthalmos, decreased blinking, corneal drying), and nasal deformities from involvement of nasal mucosa. Reactive episodes (type 1 or reversal reaction, and type 2 or erythema nodosum leprosum) represent acute complications that can cause additional neural damage if not treated promptly. Prevention of disabilities through early diagnosis, appropriate treatment, and self-care is fundamental.

8. Is there a vaccine against leprosy?

Currently, there is no specific and highly effective vaccine against leprosy. Studies have demonstrated that the BCG vaccine (Bacillus Calmette-Guérin), originally developed against tuberculosis, offers some cross-protection against leprosy, with variable efficacy among different populations. In some endemic regions, BCG vaccination is recommended for contacts of leprosy patients as a chemoprophylaxis measure. Research continues to be developed to identify more specific and effective vaccines, but to date, control strategies are based mainly on early diagnosis, appropriate treatment, and contact surveillance.

Conclusion:

Appropriate coding of leprosy using ICD-11 code 1B20 is essential for appropriate clinical management, effective epidemiological monitoring, and adequate resource allocation for control of this ancient disease that still affects vulnerable populations globally. Clear understanding of diagnostic criteria, appropriate clinical situations for code application, and differentiation of similar conditions ensures accurate documentation and contributes to global efforts to eliminate leprosy as a public health problem. Early diagnosis and timely treatment remain the fundamental pillars for preventing the disabilities that characterize advanced forms of the disease and for interrupting the chain of transmission in the community.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Leprosy

Compartir